- Home
- ADXN vs KZIA Comparison
ADXN vs KZIA Comparison
Compare ADXN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | KZIA |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | Switzerland | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ADXN | KZIA |
|---|---|---|
| Price | $7.80 | $6.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 3.1K | ★ 250.6K |
| Earning Date | 12-04-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $198,824.00 | ★ $1,199,108.00 |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $2.86 |
| 52 Week High | $12.05 | $17.40 |
Technical Indicators
Market Signals| Indicator | ADXN | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 42.82 |
| Support Level | $7.70 | $5.30 |
| Resistance Level | $8.37 | $7.11 |
| Average True Range (ATR) | 0.38 | 1.22 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 23.08 | 27.26 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.